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Objective: Interleukin-6 is a pro-inﬂammatory cytokine involved in the pathogenesis of osteoarthritis
(OA). We investigated the role of two single nucleotide polymorphisms (SNPs) mapping to the promoter
of the IL-6 gene on genetic susceptibility to hip and knee OA.
Methods: The174 G/C (rs1800795) and597 G/A (rs1800797) SNPs, implicated in the literature in risk of
hip and hand OA, were genotyped in 2511 controls, 1101 hip OA cases and 1904 knee OA cases from four
cohorts from theUK and Estonia. Datawere analysed in conjuntionwith published data on rs1800797 from
the Genetics of OA and Lifestyle study (UK) on 791 controls,1034 knee and 997 hip OA cases and rs1800795
data on 75 hip OA cases and 96 controls from Italy. Cases included both radiographic OA only and radio-
graphic and symptomatic OA. Fixed and random-effects meta-analysis models were tested.
Results: No signiﬁcant association was found with hip OA or knee OA with either SNP nor with the
haplotypes formed by them. For individual SNPs the smallest P-value for hip OA was observed using
a random-effects model for rs1800795 ORG allele¼ 1.066 (95% CI 0.89e1.28) P< 0.49, and signiﬁcant
heterogeneity between cohorts (I2¼ 65%, P< 0.034) was detected. For knee OA the smallest P-value was
seen for rs1800797 ORA allele¼ 1.055 (95%CI 0.98e1.12) P< 0.18, no signiﬁcant heterogeneity was
observed (I2¼ 0%, P< 0.68).
Conclusions: Our data do not support a role for the 174 and 597 IL-6 promoter polymorphisms in
genetic susceptibility to knee or hip OA in Caucasian populations.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most common joint disorder and
represents a leading musculoskeletal health and socioeconomic
burden. OA is not considered to be classically inﬂammatory because
of the absence of neutrophils and minimal levels of other
pro-inﬂammatory cells in the synovial ﬂuid and systemic inﬂam-
matory responses1. However, over-expression of pro-inﬂammatoryna M. Valdes, Department of
London, St Thomas Hospital,
44-(0)-207-188-6718.
).
s Research Society International. Pcytokines is common in OA and there is convincing evidence that
chondrocytes contribute to cytokine production leading to cartilage
matrixdegradation2.Moreover, the overproductionof cytokines and
growth factors from the inﬂamed synovium may play a role in the
pathophysiology of OA. The low-grade OA synovitis is itself cyto-
kine-driven, although the levels of pro-inﬂammatory cytokines are
lower than in rheumatoid arthritis (RA)2.
Interleukin-6 (IL-6) is one of the pro-inﬂammatory cytokines
involved inOApathogenesis. A signiﬁcant increase in the level of IL-6
mRNA has been detected in OA affected cartilage, and the IL-6 levels
in the serum and synovial ﬂuid have been reported to be elevated
among OA patients3. Both the mRNA expression and protein
production of IL-6, have been found to be increased in osteophytesublished by Elsevier Ltd. All rights reserved.
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mechanical stress loads were applied4 further implicating this
cytokine in OA pathogenesis. Increased IL-6 circulating serum levels
have also been shown to be associated with radiographic progres-
sion of knee OA5.
Polymorphisms in the IL-6 gene, in particular single nucleotide
polymorphisms (SNPs) at positions 174 (rs1800795), 597
(rs1800797) and 572 (rs1800796) in the promoter region of the
IL-6 gene, have been reported to be associatedwith several diseases
e.g., the extentof radiographic damage inRA6.Haplotypes formedby
these three IL-6 polymorphisms have also been implicated in total
hip arthroplasty failure7. These variants are involved in the tran-
scriptional regulation of the IL-6 gene, are associated with plasma
levels of IL-68 and have been reported to be associated with risk of
hand OA9. One of these IL-6 SNPs (rs1800795) has also been impli-
cated in risk of hip OA in an Italian caseecontrol study10. Recently,
Limer et al.11 attempted to replicate this result using rs1800797 and
found no signiﬁcant association in a large UK caseecontrol study of
hip and knee OA (Genetics of OA and Lifestyle or GOAL).
Our scope was to clarify the role of rs1800795 and rs1800797
IL-6 promoter polymorphisms on risk of knee and hip OA. To do so,
we have carried out a meta-analysis of four independent UK
cohorts (including the data from the GOAL study), one Estonian
cohort and the original Italian study on hip OA, comprising a total
of 3423 radiographic controls, 2946 knee OA cases, and 2335 hip
OA cases.Table I
Descriptive characteristics of study subjects by cohort with genotype counts and minor
Study New data
Nottingham Hertfordshire Estonia
Reference 12 13 14
Type of study Caseecontrol Population
based
Populatio
based
Origin UK UK Estonia
Age mean (SD) 67.7 (9.1) 65.5 (2.7) 47.1 (6.4
Range (40e96) (60e72) (32e60)
BMI mean (SD) 28.0 (4.9) 27.1 (4.3) 28.1 (5.4
Range (15e51) (16e48) (15e47)
F% 59% 49% 69%
Controls Deﬁnition Hip and knee
ROA- & Sx-
TF K/L <2 TF K/L <
n 736 784 448
rs1800795 CC/CG/GG (C%) 122/373/241
(41.9%)
143/354/287
(40.8%)
102/244/
(50.0%)
rs1800797 AA/AG/GG (A%) 118/372/245
(41.3%)
135/359/299
(39.6%)
96/247/1
(48.5%)
Knee OA Deﬁnition TF K/L 2
(80% TKR)
TF K/L 2 TF K/L 
n 1435 145 69
rs1800795 CC/CG/GG (C%) 283/660/492
(42.7%)
24/72/49
(41.3%)
18/40/11
(55.0%)
rs1800797 AA/AG/GG (A%) 273/663/497
(42.1%)
22/75/53
(39.6%)
16/42/11
(53.6%)
Hip OA Deﬁnition THR N/A N/A
n 1024
rs1800795 CC/CG/GG (C%) 196/511/317
(44.0%)
N/A N/A
rs1800797 AA/AG/GG (A%) 188/505/333
(42.9%)
N/A N/A
LD between rs1800795
and rs1800797
D0 0.996 0.995 0.996
r2 0.952 0.935 0.935
Haplotype frequencies
GG/CA/CG % 56.5/42.4/1.1% 59.0/39.3/1.5% 49.3/49.2
ROA- & Sx-¼ absence of radiographic and symptomatic OA; TF¼ tibiofemoral K/L¼ Kellgr
JSN¼ joint space narrowing; JSW¼ joint space width; JSN-¼ absence of deﬁnite joint spSubjects and methods
Study subjects
A full detailed description of each study cohort, recruitment,
radiographic and clinical assessment is presented in the
supplementary methods section. Study subjects from the UK
came from two caseecontrol studies in Nottingham labelled as
“Nottingham” and “GOAL”, and from population-based cohorts
from Chingford (North London) and Hertfordshire. In addition
a population-based cohort from Estonia was included as well as
data from a published Italian study. All studies were approved by
the relevant Ethics Committee and informed consent was
obtained from all study participants. In total two hip OA repli-
cation sets and four knee OA replication sets were tested totalling
1404 controls and 1101 cases for the hip OA study and
2511 controls and 1904 cases for the knee OA study. The
descriptive characteristics of the sample size and diagnosis
criteria of each cohort are presented in Table I. A reference where
each cohort is described in detail is also included.
Genotyping data
For the Nottingham, Hertfordshire, Chingford and Estonian study
participants, genomic DNA was extracted from peripheral blood
leukocytes of affected individuals and controls using standardallele frequencies of IL-6 promoter polymorphisms rs1800795 and rs1800797
Published data
Chingford Limer et al. (GOAL) Pola et al.
15 10 11
n Population
based
Caseecontrol Caseecontrol
UK UK Italy
) 64.1 (6.0) 66.5 (7.9) 71.2 (9.6)
(53e77) (45e86)
) 26.7 (4.7) 29.3 (5.3) 28.3 (3.3)
(17e50) (17e58)
100% 49% 53%
2 Knee:
TF K/L <2
Hip: JSN- Hip and knee
ROA- & Sx-
Hip ROA- & Sx-
543 668 791 96
102 81/262/200
(39.0%)
104/327/237
(40.0%)
N/A 33/40/34 (49.5%)
09 76/264/206
(38.0%)
105/324/248
(39.4%)
151/352/287 (41.3%) N/A
2 TF K/L 2 JSN 2 or osteophyte
score >1 (78% TKR)
N/A
255 1034
41/126/88
(40.7%)
N/A N/A
44/124/92
(40.7%)
193/493/348 (42.5%) N/A
Deﬁnite JSN Croft score 3
(92% THR)
JSW 1.5 mm
and K/L 3
77 997 75
13/31/33
(37.0%)
N/A 12/30/33 (36.0%)
12/33/32
(37.0%)
176/471/350 (41.2%) N/A
0.989 N/A N/A
0.920
/1.4% 59.7/38.4/1.6% N/A N/A
en and Lawrence grade; TKR¼ total knee replacement; THR¼ total hip replacement,
ace narrowing.
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shire UK. SNPs were genotyped using the KASPar chemistry, which is
a competitive allele-speciﬁc polymerase chain reaction (PCR) SNP
genotyping system using ﬂuorescence resonance energy transfer
(FRET) quencher cassette oligos. Genotyping accuracy, as determined
fromthegenotypeconcordancebetweenduplicate samples is99.6%on
average and for this study was 100% (52 samples genotyped in dupli-
cate for each SNP). Both polymorphisms were in Hardy-Weinberg
equilibrium in controls (P> 0.05). For the genotypingmethods used in
published studies from Italy and the UK the reader is referred to the
original studies by Pola et al.10 and Limer et al.11 respectively.Statistical analysis
Allele and genotype odds ratios were calculated by comparing the
numbers among cases and controls and the P-value was computed
using a Pearson's chi-square.
In the absence of inter-study heterogeneity within samples we
constructedaManteleHaenszelmeta-analysisofdata fromthesamples
to assess the overall evidence of association. TheManteleHaenszel chi-
squared test and theManteleHaenszel estimateof theodds ratio (OR)16
were used to provide a summary test and odds ratio.
Random-effects meta-analysis: In the DerSimonian and Laird
method, studies are considered as a random sample from a pop-
ulation of studies. The random effect model incorporates the
heterogeneity of the studies. The overall treatment effect is esti-
mated by a weighted average of the individual effects with weights
inversely proportional to the variance of the observed effects. We
tested the assumption of heterogeneity for each planned analysis
using the method of DerSimonian and Laird based on work ﬁrst
presented by Cochran17. The statistical signiﬁcance of the combined
effect for the DerSimonianeLaird odds ratio was estimated using
the Z-statistic which is the ratio of the point estimate to its standard
error.
Linkage disequilibrium (LD): The normalized gametic disequi-
librium coefﬁcient (D0), the squared correlation coefﬁcient between
rs1800795 and rs1800797 and the case and control haplotypesTable II
Meta-analysis results for association between rs1800795 and rs1800797 alleles and hap
Trait Cohorts included OR for allele Fixed
effects
OR
95% CI P-val
assoc
Knee OA GOAL, Nottingham,
Chingford, Hertfordshire,
Estonia
rs1800795C 1.042 0.963e1.127 0.30
Knee OA GOAL, Nottingham,
Chingford,
Hertfordshire, Estonia
rs1800797A 1.055 0.975e1.140 0.18
Hip OA GOAL, Nottingham,
Chingford, Italy
rs1800795C 1.003 0.916e1.097 0.95
Hip OA GOAL, Nottingham,
Chingford, Italy
rs1800797A 0.994 0.908e1.087 0.90
Hip OA GOAL, Nottingham,
Chingford
rs1800797A 1.020 0.930e1.118 0.67
Trait Cohorts included OR for haplotype
rs1800795-
rs1800797
Fixed
effects
OR
95% CI P-val
assoc
Knee OA Nottingham, Chingford,
Hertfordshire, Estonia
GG 0.960 0.860e1.072 0.47
Knee OA Nottingham, Chingford,
Hertfordshire, Estonia
CA 1.029 0.920e1.149 0.62
Knee OA Nottingham, Chingford,
Hertfordshire, Estonia
CG 1.307 0.824e2.073 0.25
Hip OA Nottingham, Chingford GG 0.926 0.807e1.062 0.27
Hip OA Nottingham, Chingford CA 1.058 0.921e1.214 0.43
Hip OA Nottingham, Chingford CG 1.476 0.776e2.805 0.23counts were estimated in the Estonian, Nottingham, Hertfordhire
and Chingford samples using Haploview v 4.1 (www.broad.mit.
edu/mpg/haploview/).Results
Before undertaking the project we assessed the statistical power
of our study and given the frequency of the minor allele and the
sample sizes available we estimated that we had 80% to ﬁnd
associations with an OR¼ 1.12 for hip OA and OR¼ 1.10 for knee OA
with P< 0.05.
The genotype counts for cases and controls in each are pre-
sented in Table I and the summary results of hip and knee OAmeta-
analyses for both SNPs are presented in Table II. No signiﬁcant
association was found with hip OA or knee OAwith either SNP. The
results between males and females did not differ signiﬁcantly and
no statistically signiﬁcant association with OA (P< 0.20) was seen
when genders were analysed separately (not shown).
We did ﬁnd signiﬁcant heterogeneity for hip OAwhen the Italian
data were included, excluding the Italian subjects eliminated the
heterogeneity but did not result in a smaller P-value with hip OA
(Table II). No heterogeneity was found for either rs1800795 or
rs1800797 with knee OA and neither SNP showed a signiﬁcant
association. Although there appears to be not-statistically signiﬁcant
trend (P< 0.18) for the A allele to be associated with increased risk it
is worth pointing out that this association is exactly in the opposite
direction to the one reported with hand OA9 and with hip OA10.
The smallest P-value for hip OA was observed using a DerSimo-
nianeLaird random-effects model for rs1800795. The odds ratios
for individual cohorts along with the summary random-effects
odds ratio are shown in Fig. 1(A). For knee OA the smallest P-value
was seen for rs1800797 and the individual cohort odds ratios along
with the summary ManteleHaenszel ﬁxed effects odds ratio is
shown in Fig. 1(B).
We also investigated, in the cohorts where both promoter SNPs
were genotyped, if there could be a genetic association with the
haplotypes deﬁned by these two promoter polymorphisms. Givenlotypes and hip and knee OA
ue
iation
Q df P-value
heterogeneity
I2 Random-
effects
OR
95%CI P-value
association
1.10 4 0.89 0.00% 1.042 0.963e1.127 0.30
1.23 4 0.87 0.00% 1.055 0.975 -1.140 0.18
8.69 3 0.034 65.47% 0.938 0.781e1.125 0.49
7.71 3 0.052 61.07% 0.940 0.792e1.116 0.48
0.76 2 0.68 0.00% 1.020 0.930e1.118 0.67
ue
iation
Q df P-value
heterogeneity
I2 Random-
effects
OR
95%CI P-value
association
2.52 3 0.48 0.00% 0.960 0.860e1.072 0.47
2.64 3 0.45 0.00% 1.029 0.920e1.149 0.61
2.98 3 0.39 0.00% 1.357 0.858e2.146 0.19
0.68 1 0.41 0.00% 0.926 0.807e1.062 0.27
0.84 1 0.36 0.00% 1.058 0.921e1.214 0.43
0.04 1 0.84 0.00% 1.467 0.775e2.775 0.24
Fig. 1. Forest plot of study-speciﬁc estimates and ﬁxed effects summary odds ratio (OR) and 95% conﬁdence intervals for (A) the association between the A (minor) allele at
rs1800797 and knee OA. (B) The association between the G (major) allele at rs1800795 and hip OA. *For the GOAL study, data refer to the odds ratio for the G allele at rs1800797.
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deﬁned by these SNPs and the frequencies in each cohort are
shown in Table I. No signiﬁcant association with any of these
haplotypes was seen with hip or knee OA and no signiﬁcant
heterogeneity between cohorts was observed (Table II). For both
hip and knee OA the rare “CG” haplotypes appears to be increased
in OA cases relative to controls.
Discussion
Our data do not support a genetic association between two IL-6
promoter polymorphisms and knee or hip OA either individually or
as haplotypes. Although it is possible that these individual SNPs
could be associated with hip or knee OA, the genetic effect wouldneed to be very small, i.e., an odds ratio under 1.10 which our study
was powered to detect. For the rare haplotypes “CG” with
a frequency <1.5% the sample size required to ﬁnd as signiﬁcant
a genetic association of the magnitude observed with 80% statis-
tical power is n¼ 5450 cases and 5450 controls. Our data cannot
exclude an association due to this rare haplotype. Alternatively
a role for these variants might apply only to a subset of clinical
populations not stratiﬁed in our study.
We note some potential study limitations. Our data was
derived exclusively from subjects of European descent, therefore
it may be that results do not apply to cases from other ethnicities.
Another potential limitation is that of the heterogeneity between
cohorts and the mixture between radiographic and clinical
phenotypes. The data in this study derive from three caseecontrol
A.M. Valdes et al. / Osteoarthritis and Cartilage 18 (2010) 699e704 703studies and three population-based cohorts, yet in terms of the
genetic effects we ﬁnd no evidence of heterogeneity between
cohorts for knee OA.
For hip OA, however, we observed signiﬁcant heterogeneity
between the Italian study and the other studies included. The
subjects investigated by Pola et al.10 were affected by severe hip OA,
radiographically and clinically to require a THR and the UK study
cohorts were for the most part also severe hip OA or THR so the
heterogeneity appears unlikely to be introduced by the clinical
deﬁnitions used.
For knee OA all radiographic data refer to tibiofemoral OA, we
have not investigated the role of IL-6 SNPs on patellofemoral OA
and hence we cannot exclude an association with OA in a different
joint compartment as has been reported for other genes17. Further,
given the reported associations with hand OA there may be
differences between generalized OA cases and non-generalized OA
cases which we have not explored in this study.
Studies in animal models suggest that IL-6 may have some
protective effects in the joint. IL-6 has been reported to induce
the expression of the tissue inhibitor of metalloproteinases and
stimulate proteoglycan synthesis when injected into the joints
of mice with antigen-induced arthritis18. IL-6 knock-out male
mice develop more severe spontaneous OA than wildtype
animals19. In addition, recent reports have shown that non-
steroid anti-inﬂammatory drugs (NSAIDs) increases IL-6-induced
production of MMPs from human chondrocytes, while
completely inhibiting the IL-6/sIL-6R-induced production of
prostaglandin E220. This dual role of IL-6 in the OA pathogenesis
could in part explain the lack of genetic association observed
with risk of OA. As only two of the cohorts (Estonia and
Chingford) have longitudinal data we did not explore the role on
disease progression, but given that serum levels of IL-6 have
been found in the Chingford Study to be a signiﬁcant predictor
of knee OA radiographic progression5 a role for these variants in
OA progression cannot be excluded.
Our ﬁndings appear to share some similarity with RA. Extensive
evidence suggests that dysregulation of IL-6 contributes to both
systemic and local RA symptoms21 as well as OA symptoms3.
Nevertheless, different genotypes in the IL-6 promoter poly-
morphisms do not increase susceptibility to RA22,23, conﬁrming
that lack of genetic association does not imply a lack of involvement
in disease. Further, the IL-6 promoter polymorphisms appear to
inﬂuence disease severity in RA6,22,23. It is thus possible that,
analogously, an association may exist between of IL-6 SNPs and
measures of OA severity, or with speciﬁc disease phenotypes such
as synovitis in OA.
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